van der Geest, Astrid T.
Jakobs, Channa E.
Ljubikj, Tijana
Huffels, Christiaan F. M.
Cañizares Luna, Marta
Vieira de Sá, Renata
Adolfs, Youri
de Wit, Marina
Rutten, Daan H.
Kaal, Marthe
Zwartkruis, Maria M.
Carcolé, Mireia
Groen, Ewout J. N.
Hol, Elly M.
Basak, Onur
Isaacs, Adrian M.
Westeneng, Henk-Jan
van den Berg, Leonard H.
Veldink, Jan H.
Schlegel, Domino K.
Pasterkamp, R. Jeroen http://orcid.org/0000-0003-1631-6440
Funding for this research was provided by:
Stichting ALS Nederland (TOTALS, ALS-on-a-chip, MUS-ALS, ATAXALS, GoALS)
ALS Cure project
E-Rare (INTEGRALS)
JPND (TRIAGE)
Rudolf Magnus fellowship
European Research Council (EScORIAL)
UK Dementia Research Institute
Article History
Received: 21 August 2024
Accepted: 24 August 2024
First Online: 18 September 2024
Declarations
:
: The medical ethical approval committee (METC) of University Medical Center Utrecht granted approval for iPSC line generation through biobank protocol 16-436. Donors had provided written informed consent. Patients were diagnosed according to the diagnostic criteria for ALS (revised El Escorial). Details of human subjects and iPSC lines can be found in Supplementary Table 1.
: Not applicable.
: J.H.V. reports to have sponsored research agreements with Biogen and Astra Zeneca. R.J.P. reports to have sponsored research agreements with Amylyx. The other authors declare no competing interests.